Otsuka Pharmaceutical Development & Commercialization, Inc.

This study tested whether adding a new medication called SEP-363856 to a person's current antidepressant could help reduce depression symptoms more effectively. It involved 929 adults whose depression had not improved enough with standard antidepressants alone. Researchers compar…

This study aimed to understand the long-term safety and side effects of the medication brexpiprazole in teenagers (ages 13-17) with schizophrenia. Nearly 300 adolescents took a flexible dose of the drug for up to two years while researchers closely monitored their health. The mai…

This study tested whether a new, once-daily pill called centanafadine could help reduce binge eating days in adults with moderate to severe binge eating disorder. Researchers compared two different doses of the medication against a placebo (a pill with no medicine) in 147 partici…

This study tested how well people with schizophrenia could switch from their current antipsychotic medication to a new drug called SEP-363856. 101 participants took the new drug for 8 weeks while researchers monitored how many stopped treatment due to side effects or lack of bene…

This study tested the long-term safety of an experimental schizophrenia medication called SEP-363856. It involved 75 people with schizophrenia who had already switched to this drug from their previous antipsychotic medication in an earlier trial. Researchers monitored participant…

This early-stage study tested different capsule versions of an experimental drug called centanafadine, which is being developed for ADHD. Researchers gave the pills to 174 healthy adults to see if different capsule strengths worked the same, if food affected absorption, and how t…

This first-in-human study tested the safety and how the body processes CAN10, a new antibody being developed for plaque psoriasis. The trial involved 80 healthy volunteers and people with mild to moderate psoriasis, testing single and repeated doses. Researchers monitored side ef…

This study aimed to see if a new, experimental schizophrenia medication called SEP-363856 is safe for people to take for a full year. It compared the drug's long-term safety and side effects to an already-approved medication, quetiapine XR. The trial involved 305 clinically stabl…

This study tested whether an investigational drug called AVP-786 could help reduce severe behavioral problems like aggression, agitation, and irritability in people who have had a traumatic brain injury (TBI). 168 participants were randomly assigned to receive either the drug or …

This clinical trial tested whether an investigational medication called SEP-363856 could safely reduce anxiety symptoms in adults with generalized anxiety disorder. About 434 participants across roughly 65 global sites took either the medication or a placebo pill daily for 8 week…

This study aimed to see if taking two smaller capsules of the drug centanafadine is equivalent to taking one larger capsule. It involved 44 healthy adult participants who took the drug in different forms to compare how their bodies processed it. The goal was to gather data to sup…

This early-stage study tested how the body absorbs two different versions of the experimental drug centanafadine: a new sustained-release tablet and an existing extended-release capsule. The trial involved 62 healthy adult volunteers to measure and compare drug levels in the bloo…

This study tested how a potential new schizophrenia medication (SEP-380135) might interact with other drugs in the body. Researchers gave healthy adult participants the study drug along with another medication that affects how drugs are processed. The goal was to understand poten…

This early-stage study aimed to understand how a new drug called OPC-167832 is processed by the body. Eight healthy male volunteers took a single oral dose containing a tiny, safe amount of radioactive tracer. Researchers then measured how much of the drug was absorbed, how long …